Protease-activated receptors in cardiovascular diseases

Circulation

Volumn 114, Issue 10, 2006, Pages 1070-1077

  Leger, Andrew J ^a   Covic, Lidija ^a   Kuliopulos, Athan ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

Arteries; Endothelium; Inhibitors; Platelets; Receptors; Signal transduction; Thrombosis

Indexed keywords

G PROTEIN COUPLED RECEPTOR; PEPDUCIN; PROTEIN INHIBITOR; PROTEINASE ACTIVATED RECEPTOR; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 4; THROMBIN; UNCLASSIFIED DRUG;

ARTERY INTIMA PROLIFERATION; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CELL ACTIVATION; CELL FUNCTION; CLINICAL TRIAL; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; RECEPTOR UPREGULATION; RESTENOSIS; REVIEW; SCREENING TEST; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; THROMBOCYTE; THROMBOSIS; VASCULAR ENDOTHELIUM;

HUMANS; PLATELET ACTIVATION; RECEPTOR, PAR-1; RECEPTORS, THROMBIN; SIGNAL TRANSDUCTION; THROMBOSIS;

EID: 33748495552     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.574830     Document Type: Review

References (76)

1. Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor action. Cell. 1991;64:1057-1068.
2. Nelken NA, Soifer SJ, O'Keefe J, Vu TK, Charo IF, Coughlin SR. Thrombin receptor expression in normal and atherosclerotic human arteries. J Clin Invest. 1992;90:1614-1621.
3. Ku DD, Dai J. expression of thrombin receptors in human atherosclerotic coronary arteries leads to an exaggerated vasoconstrictory response in vitro. J Cardiovasc Pharmacol. 1997;30:649-657.
4. Takada M, Tanaka H, Yamada T, Ito O, Kogushi M, Yanagimachi M, Kawamura T, Musha T, Yoshida F, Ito M, Kobayashi H, Yoshitake S, Saito I. Antibody to thrombin receptor inhibits neointimal smooth muscle cell accumulation without causing inhibition of platelet aggregation or altering hemostatic parameters after angioplasty in rat. Circ Res. 1998;82:980-987.
5. Vergnolle N, Wallace JL, Bunnett NW, Hollenberg MD. Protease-activated receptors in inflammation, neuronal signaling and pain. Trends Pharmacol Sci. 2001;22:146-152.
6. Harker LA, R.Hanson S, Kelly AB. Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation. Thromb Haemost. 1997;78:736-741.
7. Ault KA, Cannon CP, Mitchell J, McCahan J, Tracy RP, Novotny WF, Reiman JD, Braunwald E. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 Trial. J Am Coll Cardiol. 1999;33:634-639.
8. Ruggeri ZM. Platelets in atherothrombosis. Nat Med. 2002;8:1227-1234.
9. Xu W-F, Andersen H, Whitmore TE, Presnell SR, Yee DP, Ching A, Gilbert T, Davie EW, Foster DC. Cloning and characterization of human protease-activated receptor 4. Proc Natl Acad Sci U S A. 1998;95:6642-6646.
10. Kahn ML, Zheng Y-W, Huang W, Bigornia V, Zheng D, Moff S, Farese RV, Tam C, Coughlin SR. A dual thrombin receptor system for platelet activation. Nature. 1998;394:690-694.
11. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest. 1999;103:879-887.
12. Covic L, Gresser AL, Kuliopulos A. Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets. Biochemistry. 2000;39:5458-5467.
13. Covic L, Gresser AL, Talavera J, Swift S, Kuliopulos A. Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides. Proc Natl Acad Sci U S A. 2002;99:643-648.
14. Covic L, Misra M, Badar J, Singh C, Kuliopulos A. Pepducin-based intervention of thrombin receptor signaling and systemic platelet activation. Nat Med. 2002;8:1161-1165.
15. Boire A, Covic L, Agarwal A, Jacques S, Sharifi S, Kuliopulos A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell. 2005;120:303-313.
16. Kaneider NC, Agarwal A, Leger AJ, Kuliopulos A. Reversing systemic inflammatory response syndrome with chemokine receptor pepducins. Nat Med. 2005;11:661-665.
17. Leger A, Jacques SL, Badar J, Kaneider NC, Derian CK, Andrade-Gordon P, Covic L, Kuliopulos A. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. Circulation. 2006;113:1244-1254.
18. Gerszten RE, Chen J, Ishii M, Ishii K, Wang L, Nanevicz T, Turck CW, Vu T-KH, Coughlin ST. Specificity of the thrombin receptor for agonist peptide is defined by its extracellular surface. Nature. 1994;368:648-651.
19. Bahou WF, Kutok JL, Wong A, Potter CL, Coller BS. Identification of a novel thrombin receptor sequence required for activation-dependent responses. Blood. 1994;84:4195-4202.
20. Nanevicz T, Ishii M, Wang L, Chen M, Chen J, Turck CW, Cohen FE, Coughlin SR. Mechanisms of thrombin receptor agonist specificity. J Biol Chem. 1995;270:21619-21625.
21. Seeley S, Covic L, Jacques SL, Sudmeier J, Baleja JD, Kuliopulos A. Structural basis for thrombin activation of a protease-activated receptor: inhibition of intramolecular liganding. Chem Biol. 2003;10:1033-1041.
22. Vu T-KH, Wheaton VI, Hung DT, Charo I, Coughlin SR. Domains specifying thrombin-receptor interaction. Nature. 1991;353:674-677.
23. Liu LW, Vu T, Esmon CT, Coughlin SR. The region of the thrombin receptor resembling hirudin binds to thrombin and alters enzyme specificity. J Biol Chem. 1991;266:16977-16980.
24. Mathews II, Padmanabhan KP, Ganesh V, Tulinsky A, Ishii M, Chen J, Turck CE, Coughlin SR, Fenton JW. Crystallographic structures of thrombin complexes with thrombin receptor peptides: existence of expected and novel binding modes. Biochemistry. 1994;33:3266-3279.
25. Ishii K, Gerszten R, Zheng YW, Welsh JB, Turck CW, Coughlin SR. Determinants of thrombin receptor cleavage. J Biol Chem. 1995;270:16435-16440.
26. Jacques S, LeMasurier M, Sheridan PJ, Seeley SK, Kuliopulos A. Substrate-assisted catalysis of the PAR1 thrombin receptor: enhancement of macromolecular association and cleavage. J Biol Chem. 2000;275:40671-40678.
27. Candia ED, Hall SW, Rutella S, Landolfi R, Andrews RK, Cristofaro RD. Binding of thrombin to glycoprotein Ib accelerates the hydrolysis of PAR1 on intact platelets. J Biol Chem. 2001;276:4692-4698.
28. q-deficient mice. Nature. 1997;389:183-186.
29. Trumel C, Payrastre B, Plantavid M, Hechler B, Viala C, Presek P, Martinson EA, Cazenave J-P, Chap H, Gachet C. A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1-activating peptide through the late activation of phosphoinositide 3-kinase. Blood. 1999;94:4156-4165.
30. Covic L, Singh C, Smith H, Kuliopulos A. Role of the PAR4 thrombin receptor in stabilizing platelet-platelet aggregates as revealed by a patient with Hermansky-Pudlak syndrome. Thromb Haemost. 2002;87:722-727.
31. Nakanishi-Matsui M, Zheng Y-W, Sulciner DJ, Weiss EJ, Ludeman MJ, Coughlin SR. PAR3 is a cofactor for PAR4 activation by thrombin. Nature. 2000;404:609-613.
32. Jacques SL, Kuliopulos A. Protease-activated receptor-4 uses dual prolines and an anionic recognition motif for thrombin recognition and cleavage. Biochem J. 2003;376:733-740.
33. Kimmelstiel C, Badar J, Covic L, Waxman S, Weintraub A, Kuliopulos A. Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel. Thromb Res. 2005;116:55-66.
34. Sambrano GR, Weiss EJ, Zheng YW, Huang W, Coughlin SR. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature. 2001;413:74-78.
35. Mirza H, Yatsula V, Bahou WF. The proteinase activated receptor-2 (PAR-2) mediates mitogenic responses in human vascular endothelial cells. J Clin Invest. 1996;97:1705-1714.
36. Schmidt VA, Nierman WC, Maglott DR, Cupit LD, Moskowitz KA, Wainer JA, Bahou WF. The human proteinase-activated receptor-3 (PAR-3) gene. J Biol Chem. 1998;273:15061-15068.
37. Kataoka H, Hamilton JR, McKemy DD, Camerer E, Zheng Y-W, Cheng A, Griffin C, Coughlin SR. Protease-activated receptors 1 and 4 mediate thrombin signaling in endothelial cells. Blood. 2003;102:3224-3231.
38. Fujiwara M, Jin E, Ghazizadeh M, Kawanami O. Activation of PAR4 induces a distinct actin fiber formation via p38 MAPK in human lung endothelial cells. J Histochem Cytochem. 2005;53:1121-1129.
39. Ossovskaya VS, Bunnett NW. Protease-activated receptors: contribution to physiology and disease. Physiol Rev. 2004;84:579-621.
40. Camerer E, Huang W, Coughlin SR. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci U S A. 2000;97:5255-5260.
41. Riewald M, Ruf W. Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor. Proc Natl Acad Sci U S A. 2001;98:7742-7747.
42. 2+ mobilization, barrier dysfunction, prostaglandin synthesis, and platelet-derived growth factor mRNA expression in cultured endothelium. J Cell Physiol. 1993;156:541-549.
43. Hattori R, Hamilton KK, Fugate RD, McEver RP, Sims PJ. Stimulated secretion of endothelial von Willebrand factor is accompanied by rapid redistribution to the cell surface of the intracellular granule membrane protein GMP-140. J Biol Chem. 1989;264:7768-7771.
44. Andre P, Denis CV, Ware J, Saffaripour S, Hynes RO, Ruggeri ZM, Wagner DD. Platelets adhere to and translocate on von Willebrand factor presented by endothelium in stimulated veins. Blood. 2000;96:3322-3328.
45. Garcia JG, Davis HW, Patterson CE. Regulation of endothelial cell gap formation and barrier dysfunction: role of myosin light chain phosphorylation. J Cell Physiol. 1995;163:510-522.
46. Vouret-Craviari V, Bourcier C, Boulter E, van Obberghen-Schilling E. Distinct signals via Rho GTPases and Src drive shape changes by thrombin and sphingosine-1-phosphate in endothelial cells. J Cell Sci. 2002;115:2475-2484.
47. Minami T, Sugiyama A, Wu SQ, Abid R, Kodama T, Aird WC. Thrombin and phenotypic modulation of the endothelium. Arterioscler Thromb Vasc Biol. 2004;24:41-53.
48. Camerer E, Kataoka H, Kahn M, Lease K, Coughlin SR. Genetic evidence that protease-activated receptors mediate factor Xa signaling in endothelial cells. J Biol Chem. 2002;277:16081-16087.
49. Rao LV, Pendurthi UR. Tissue factor-factor VIIa signaling. Arterioscler Thromb Vasc Biol. 2005;25:47-56.
50. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science. 2002;296:1880-1882.
51. Mosnier LO, Gale AJ, Yegnesaran S, Griffin JH. Activated protein C variants with normal cytoprotective but reduced anticoagulant activity. Blood. 2004;104:1740-1744.
52. Feistritzer C, Lenta R, Riewald M. Protease-activated receptors-1 and -2 can mediate endothelial barrier protection: role in factor Xa signaling. J Thromb Haemost. 2005;3:2798-2805.
53. Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood. 2005;105:3178-3184.
54. McNamara CA, Sarembock IJ, Gimple LW, Fenton J, Coughlin SR, Owens GK. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. J Clin Invest. 1993;91:94-98.
55. Sukhova GK, Schonbeck U, Rabkin E, Schoen RJ, Poole AR, Billinghurst RC, Libby P. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation. 1999;99:2503-2509.
56. Morgan AR, Rerkasem K, Gallagher PJ, Zhang B, Morris GE, Calder PC, Grimble RF, Eriksson P, McPheat WL, Shearman CP, Ye S. Differences in matrix metalloproteinase-1 and matrix metalloproteinase-12 transcript levels among carotid atherosclerotic plaques with different histopathological characteristics. Stroke. 2004;35:1310-1315.
57. Glembotski CC, Irons CE, Krown KA, Murrey SF, Sprenkle AB, Sei CA. Myocardial α-thrombin receptor activation induces hypertrophy and increases atrial natriuretic factor gene expression. J Biol Chem. 1993;268:20646-20652.
58. Sabri A, Muske G, Zhang H, Pak E, Darrow A, Andrade-Gordon P, Steinberg SF. Signaling properties and functions of two distinct cardiomyocyte protease-activated receptors. Circ Res. 2000;86:1054-1061.
59. Ku DD, Zaleski JK. Receptor mechanism of thrombin-induced endothelium-dependent and endothelium-independent coronary vascular effects in dogs. J Cardiovasc Pharmacol. 1993;22:609-616.
60. Cheung W, Andrade-Gordon P, Derian CK, Damiano BP. Receptor activating peptides distinguish thrombin receptor (PAR1) and protease-activated receptor-2 (PAR2)-mediated hemodynamic responses in vivo. Can J Physiol Pharmacol. 1998;76:16-25.
61. Damiano BP, Cheung WM, Santulli RJ, Fung-Leung WP, Ngo K, Ye RD, Darrow AL, Derian CK, de Garavilla L, Andrade-Gordon P. Cardiovascular responses mediated by protease-activated receptor-2 (PAR-2) and thrombin receptor (PAR-1) are distinguished in mice deficient in PAR-2 or PAR-1. J Pharmacol Exp Ther. 1999;288:671-678.
62. Darrow AL, Fung-Leung W-P, Ye RD, Santulli RJ, Cheung W-M, Derian CK, Burns CL, Damiano BP, Zhou L, Keenan CM, Peterson PA, Andrade-Gordon P. Biological consequences of thrombin receptor deficiency in mice. Thromb Haemost. 1996;76:860-866.
63. Cook JJ, Sitko GR, Bednar B, Condra C, Mellot MJ, Feng D-M, Nutt RF, Shafer JA, Gould RJ, Connolly TM. An antibody against the exosite of the cloned thrombin receptor inhibits experimental arterial thrombosis in the African green monkey. Circulation. 1995;91:2961-2971.
64. Bernatowicz MS, Klimas CE, Hartl KS, Peluso M, Allegretto NJ, Seiler SM. Development of potent thrombin receptor antagonist peptides. J Med Chem. 1996;39:4879-4887.
65. Andrade-Gordon P, Maryanoff BE, Derian CK, Zhang H-C, Addo MF, Darrow AL, Eckardt AJ, Hoekstra WJ, McComsey DF, Oksenberg D, Reynolds EE, Santulli RJ, Scarborough RM, Smith CE, White KB. Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor. Proc Natl Acad Sci U S A. 1999;96:12257-12262.
66. Zhang HC, Derian CK, Andrade-Gordon P, Hoekstra WJ, McComsey DF, White KB, Poulter BL, Addo MF, Cheung WM, Damiano BP, Oksenberg D, Reynolds EE, Pandey A, Scarborough RM, Maryanoff BE. Discovery and optimization of a novel series of thrombin receptor (PAR-1) antagonists: potent, selective peptide mimetics based on indole and indazole templates. J Med Chem. 2001;44:1021-1024.
67. Andrade-Gordon P, Derian CK, Maryanoff BE, Zhang H-C, Addo MF, Cheung W-M, Damiano BP, D'Andrea MR, Darrow AL, DeGaravilla L, Eckardt AJ, Giardino EC, Haertlein BJ, McComsey DF. Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats. J Pharmacol Exp Ther. 2001;298:34-42.
68. Derian CK, Damiano BP, Addo MF, Darrow AL, D'Andrea MR, Nedelman M, Zhang HC, Maryanoff BE, Andrade-Gordon P. Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J Pharmacol Exp Ther. 2003;304:855-861.
69. Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov. 2003;2:15-28.
70. Chackalamannil S, Xia Y, Greenlee WJ, Clasby M, Doller D, Tsai H, Asberom T, Czarniecki M, Ahn HS, Boykow G, Foster C, Agans-Fantuzzi J, Bryant M, Lau J, Chintala M. Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents. J Med Chem. 2005;48:5884-5887.
71. Stampfuss JJ, Schror K, Weber AA. Inhibition of platelet thromboxane receptor function by a thrombin receptor-targeted pepducin. Nat Med. 2003;9:1447-1448.
72. Majumdar M, Tarui T, Shi B, Akakura N, Ruf W, Takada Y. Plasmin-induced migration requires signaling through protease-activated receptor 1 and integrin alpha(9)beta(1). J Biol Chem. 2004;279:37528-37534.
73. Hollenberg MD, Saifeddine M, Sandhu S, Houle S, Vergnolle N. Proteinase-activated receptor-4: evaluation of tethered ligand-derived peptides as probes for receptor function and as inflammatory agonists in vivo. Br J Pharmacol. 2004;143:443-454.
74. Keuren JF, Wielders SJ, Ulrichts H, Hackeng T, Heemskerk JW, Deckmyn H, Bevers EM, Lindhout T. Synergistic effect of thrombin on collagen-induced platelet procoagulant activity is mediated through protease-activated receptor-1. Arterioscler Thromb Vasc Biol. 2005;25:1499-1505.
75. Houle S, Papez MD, Ferazzini M, Hollenberg MD, Vergnolle N. Neutrophils and the kallikrein-kinin system in proteinase-activated receptor 4-mediated inflammation in rodents. Br J Pharmacol. 2005;146:670-678.
76. Covic L, Tchernychev B, Jacques S, Kuliopulos A. Pharmacology and in vivo efficacy of pepducins in hemostasis and arterial thrombosis. In Langel U, ed. Handbook of Cell-Penetrating Peptides. 2nd ed. London, UK: CRC Press; 2006:245-257.